Wedge SR - Search Results

1

Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4.

Myers SM, Miller DC, Molyneux L, Arasta M, Bawn RH, Blackburn TJ, Cook SJ, Edwards N, Endicott JA, Golding BT, Griffin RJ, Hammonds T, Hardcastle IR, Harnor SJ, Heptinstall AB, Lochhead PA, Martin MP, Martin NC, Newell DR, Owen PJ, Pang LC, Reuillon T, Rigoreau LJM, Thomas HD, Tucker JA, Wang LZ, Wong AC, Noble MEM, Wedge SR, Cano C. Myers SM, et al. Among authors: wedge sr. Eur J Med Chem. 2019 Sep 15;178:530-543. doi: 10.1016/j.ejmech.2019.05.057. Epub 2019 May 25. Eur J Med Chem. 2019. PMID: 31212132

2

Measurement of 5,10-dideaza-5,6,7,8-tetrahydrofolate (lometrexol) in human plasma and urine by high-performance liquid chromatography.

Wedge SR, Laohavinij S, Taylor GA, Newell DR. Wedge SR, et al. J Chromatogr B Biomed Appl. 1995 Jan 20;663(2):327-35. doi: 10.1016/0378-4347(94)00441-7. J Chromatogr B Biomed Appl. 1995. PMID: 7735480 Clinical Trial.

3

Pharmacokinetics of high molecular weight agents.

Cassidy J, Newell DR, Wedge SR, Cummings J. Cassidy J, et al. Among authors: wedge sr. Cancer Surv. 1993;17:315-41. Cancer Surv. 1993. PMID: 8137346 Review.

4

A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.

Laohavinij S, Wedge SR, Lind MJ, Bailey N, Humphreys A, Proctor M, Chapman F, Simmons D, Oakley A, Robson L, Gumbrell L, Taylor GA, Thomas HD, Boddy AV, Newell DR, Calvert AH. Laohavinij S, et al. Among authors: wedge sr. Invest New Drugs. 1996;14(3):325-35. doi: 10.1007/BF00194536. Invest New Drugs. 1996. PMID: 8958188 Clinical Trial.

5

Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10- dideaza-5,6,7,8-tetrahydrofolic acid (Lometrexol) administered with an oral folic acid supplement.

Wedge SR, Laohavinij S, Taylor GA, Boddy A, Calvert AH, Newell DR. Wedge SR, et al. Clin Cancer Res. 1995 Dec;1(12):1479-86. Clin Cancer Res. 1995. PMID: 9815947 Clinical Trial.

6

Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.

Hennequin LF, Stokes ES, Thomas AP, Johnstone C, Plé PA, Ogilvie DJ, Dukes M, Wedge SR, Kendrew J, Curwen JO. Hennequin LF, et al. Among authors: wedge sr. J Med Chem. 2002 Mar 14;45(6):1300-12. doi: 10.1021/jm011022e. J Med Chem. 2002. PMID: 11881999

7

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.

Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, Boffey SJ, Kilburn LL, Barnett S, Richmond GH, Wadsworth PF, Walker M, Bigley AL, Taylor ST, Cooper L, Beck S, Jürgensmeier JM, Ogilvie DJ. Wedge SR, et al. Cancer Res. 2005 May 15;65(10):4389-400. doi: 10.1158/0008-5472.CAN-04-4409. Cancer Res. 2005. PMID: 15899831

8

The kinase inhibitor O6-cyclohexylmethylguanine (NU2058) potentiates the cytotoxicity of cisplatin by mechanisms that are independent of its effect upon CDK2.

Harrison LR, Ottley CJ, Pearson DG, Roche C, Wedge SR, Dolan ME, Newell DR, Tilby MJ. Harrison LR, et al. Among authors: wedge sr. Biochem Pharmacol. 2009 May 15;77(10):1586-92. doi: 10.1016/j.bcp.2009.02.018. Epub 2009 Mar 5. Biochem Pharmacol. 2009. PMID: 19426695

9

Identification and Characterization of an Irreversible Inhibitor of CDK2.

Anscombe E, Meschini E, Mora-Vidal R, Martin MP, Staunton D, Geitmann M, Danielson UH, Stanley WA, Wang LZ, Reuillon T, Golding BT, Cano C, Newell DR, Noble ME, Wedge SR, Endicott JA, Griffin RJ. Anscombe E, et al. Among authors: wedge sr. Chem Biol. 2015 Sep 17;22(9):1159-64. doi: 10.1016/j.chembiol.2015.07.018. Epub 2015 Aug 27. Chem Biol. 2015. PMID: 26320860 Free PMC article.

10

Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation.

Lochhead PA, Clark J, Wang LZ, Gilmour L, Squires M, Gilley R, Foxton C, Newell DR, Wedge SR, Cook SJ. Lochhead PA, et al. Among authors: wedge sr. Cell Cycle. 2016;15(4):506-18. doi: 10.1080/15384101.2015.1120915. Cell Cycle. 2016. PMID: 26959608 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

92 results

Search Page